97 related articles for article (PubMed ID: 24206095)
21. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia.
Coskun E; von der Heide EK; Schlee C; Kühnl A; Gökbuget N; Hoelzer D; Hofmann WK; Thiel E; Baldus CD
Leuk Res; 2011 Feb; 35(2):208-13. PubMed ID: 20570349
[TBL] [Abstract][Full Text] [Related]
22. Diagnosis and prognosis in acute myeloid leukemia--the art of distinction.
Löwenberg B
N Engl J Med; 2008 May; 358(18):1960-2. PubMed ID: 18450608
[No Abstract] [Full Text] [Related]
23. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow miR-10a overexpression is associated with genetic events but not affects clinical outcome in acute myeloid leukemia.
Zhang TJ; Guo H; Zhou JD; Li XX; Zhang W; Ma JC; Wen XM; Yao XY; Lin J; Qian J
Pathol Res Pract; 2018 Jan; 214(1):169-173. PubMed ID: 29254789
[TBL] [Abstract][Full Text] [Related]
25. P-glycoprotein (P-170) expression in acute leukemias.
Abd El-Ghaffar HA; Aladle DA; Farahat SE; Abd El-Hady N
Hematology; 2006 Feb; 11(1):35-41. PubMed ID: 16522547
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic regulation of miRNA genes in acute leukemia.
Agirre X; Martínez-Climent JÁ; Odero MD; Prósper F
Leukemia; 2012 Mar; 26(3):395-403. PubMed ID: 22143672
[TBL] [Abstract][Full Text] [Related]
27. [Expression and clinical significance of anti-apoptosis gene, survivin, in acute leukemia].
Lin M; Meng X; Cai Z; Ye X
Zhonghua Xue Ye Xue Za Zhi; 2002 May; 23(5):251-3. PubMed ID: 12133447
[TBL] [Abstract][Full Text] [Related]
28. microRNA-181b targets MLK2 in HL-60 cells.
Chen H; Chen Q; Fang M; Mi Y
Sci China Life Sci; 2010 Jan; 53(1):101-106. PubMed ID: 20596961
[TBL] [Abstract][Full Text] [Related]
29. Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia.
De Luca L; Trino S; Laurenzana I; Tagliaferri D; Falco G; Grieco V; Bianchino G; Nozza F; Campia V; D'Alessio F; La Rocca F; Caivano A; Villani O; Cilloni D; Musto P; Del Vecchio L
Cell Death Dis; 2017 Jun; 8(6):e2849. PubMed ID: 28569789
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance of MicroRNA-29a and MicroRNA-100 Gene Expression in Pediatric Acute Myeloid Leukemia: Erratum.
J Pediatr Hematol Oncol; 2022 Jul; 44(5):272. PubMed ID: 35731971
[No Abstract] [Full Text] [Related]
31. MicroRNA-155 expression and function in AML: An evolving paradigm.
Narayan N; Bracken CP; Ekert PG
Exp Hematol; 2018 Jun; 62():1-6. PubMed ID: 29601851
[TBL] [Abstract][Full Text] [Related]
32. Acute myeloid leukemia with translocation (8;16)(p11;p13) and MYST3-CREBBP rearrangement harbors a distinctive microRNA signature targeting RET proto-oncogene.
Díaz-Beyá M; Navarro A; Ferrer G; Díaz T; Gel B; Camós M; Pratcorona M; Torrebadell M; Rozman M; Colomer D; Monzo M; Esteve J
Leukemia; 2013 Mar; 27(3):595-603. PubMed ID: 23022987
[TBL] [Abstract][Full Text] [Related]
33. MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia.
Trino S; Lamorte D; Caivano A; Laurenzana I; Tagliaferri D; Falco G; Del Vecchio L; Musto P; De Luca L
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29401684
[TBL] [Abstract][Full Text] [Related]
34. miRNAs in chronic myeloid leukemia: small molecules, essential function.
Litwińska Z; Machaliński B
Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267
[TBL] [Abstract][Full Text] [Related]
35. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development.
Schneider E; Staffas A; Röhner L; Krowiorz K; Heuser M; Döhner K; Bullinger L; Döhner H; Fogelstrand L; Rouhi A; Kuchenbauer F; Palmqvist L
Exp Hematol; 2016 Dec; 44(12):1166-1171. PubMed ID: 27619068
[TBL] [Abstract][Full Text] [Related]
37. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
[TBL] [Abstract][Full Text] [Related]
38. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
39. miR signatures and the role of miRs in acute myeloid leukaemia.
Seca H; Almeida GM; Guimarães JE; Vasconcelos MH
Eur J Cancer; 2010 Jun; 46(9):1520-7. PubMed ID: 20413298
[TBL] [Abstract][Full Text] [Related]
40. Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208.
Tron AE; Keeton EK; Ye M; Casas-Selves M; Chen H; Dillman KS; Gale RE; Stengel C; Zinda M; Linch DC; Lai Z; Khwaja A; Huszar D
Leuk Lymphoma; 2016 Dec; 57(12):2927-2929. PubMed ID: 27189703
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
